Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

17.20 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 17.20
Bid (Size) 15.80 (1)
Ask (Size) 24.49 (1)
Prev. Close 17.20
Today's Range 17.20 - 17.20
52wk Range 3.040 - 34.99
Shares Outstanding 56,747,577
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-39.94%
-39.94%
1 Month
-30.28%
-30.28%
3 Month
-40.69%
-40.69%
6 Month
-23.93%
-23.93%
1 Year
+53.43%
+53.43%

More News

Read More
Expert Ratings for Rhythm Pharmaceuticals
Via Benzinga
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Earnings Scheduled For March 1, 2023
Via Benzinga
Rhythm Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
3 Breakout Growth Stocks to Buy for the Long Haul
Via The Motley Fool
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
From Rhythm Pharmaceuticals, Inc.
Via Globe NewsWire
Biotech Stocks Well-Positioned For The Fourth Quarter
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.